TA135 Mesothelioma - pemetrexed disodium: audit criteria

A costing statement has been produced by NICE to provide an implementation tool to estimate the financial impact to the NHS of implementing the technology appraisal TA135 ? Pemetrexed disodium for the treatment of malignant pleural mesothelioma.

The Institute would welcome feedback from users to inform the development of future templates. Please email your comments to costing@nice.org.uk .